Pravastatin sodium
(Synonyms: 普伐他汀钠; CS-514 sodium) 目录号 : GC14538
Pravastatin sodium 是一种HMG-CoA可逆的竞争性抑制剂，IC50为5.6μM，通常用于高胆固醇血症和冠心病的研究。
Cas No.:81131-70-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Pravastatin sodium is a reversible competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, with an IC50 of 5.6μM. Pravastatin sodium is commonly used in the research of hypercholesterolemia and various cardiovascular diseases[1]. HMG-CoAR is located in the cytoplasm of eukaryotic cells and some prokaryotes. The enzyme utilizes NADPH to reduce HMG-CoA to mevalonate, serving as the rate-limiting enzyme in the first stage of cholesterol biosynthesis. Critical catalytic residues of this enzyme include Lys691, Glu559, Asp767, and His866[2]. Pravastatin sodium binds to the pocket of HMG-CoAR where HMG-CoA would bind, through van der Waals forces, thereby reducing the synthesis of cholesterol[3].
In vitro, treatment with Pravastatin sodium (1μg/mL) alleviates high glucose-induced migration dysfunction in cytotrophoblast (CTB) cells incubated at varying glucose concentrations [4]. Treatment of endothelial colony-forming cells (ECFCs) with Pravastatin sodium (0-2000μM) significantly enhances cell proliferation, migration, and tube formation capabilities.Pravastatin sodium increases the phosphorylation of protein kinase B (AKT) and endothelial nitric oxide synthase (eNOS), as well as the expression levels of heme oxygenase-1 (HO-1), vascular endothelial growth factor A (VEGF-A), and placental growth factor (PlGF). Pravastatin sodium decreases the expression levels of soluble fms-like tyrosine kinase-1 (sFlt-1) and endothelial protein C receptor (Eng) [5].
In vivo, oral administration of Pravastatin sodium (20mg/kg/day) to diabetic rats for 8 weeks resulted in an increase in body weight. Pravastatin sodium significantly reduced the levels of glycogen phosphorylase, lactate dehydrogenase, and glucose-6-phosphatase, thereby improving liver enzyme abnormalities caused by diabetes. Pravastatin sodium also decreased fasting blood glucose levels and increased hepatic glycogen content [6]. Oral treatment with Pravastatin sodium (20mg/kg/day) for 14 days in mice with cardiac fibrosis induced by isoproterenol led to a reduction in CK-MB, serum triglycerides, collagen I and III levels in heart tissue, cardiac inflammatory cells, and cardiac fibrosis levels [7].
References:
[1] Raasch RH. Pravastatin sodium, a new HMG-CoA reductase inhibitor. DICP. 1991 Apr;25(4):388-94.
[2] Miziorko HM. Enzymes of the mevalonate pathway of isoprenoid biosynthesis. Arch Biochem Biophys. 2011 Jan 15;505(2):131-43.
[3] Istvan ES. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Am Heart J. 2002 Dec;144(6 Suppl):S27-32.
[4] Pantho AF, Mohamed S, Govande JV, et al. Pravastatin Protects Cytotrophoblasts from Hyperglycemia-Induced Preeclampsia Phenotype. Cells. 2024 Sep 13;13(18):1534.
[5] Meyer N, Brodowski L, Richter K, et al. Pravastatin Promotes Endothelial Colony-Forming Cell Function, Angiogenic Signaling and Protein Expression In Vitro. J Clin Med. 2021 Jan 6;10(2):183.
[6] Kaya HK, Demirtas B, Yokus B, et al. Comparative effects of pravastatin and rosuvastatin on carbohydrate metabolism in an experimental diabetic rat model. Acta Pharm. 2024 Mar 30;74(1):117-130.
[7] Rana A, Singh TU, Sharma M, et al. Pravastatin attenuates isoprenaline induced cardiac fibrosis in a mouse model. Biotech Histochem. 2023 Nov;98(8):567-577.
Pravastatin sodium 是一种HMG-CoA可逆的竞争性抑制剂，IC50为5.6μM，通常用于高胆固醇血症和冠心病的研究[1]。HMG-CoAR存在于真核生物和一些原核生物的细胞质中。HMG-CoAR利用NADPH将HMG-CoA还原为甲羟戊酸，是介导胆固醇生物合成第一阶段的限速酶，关键的催化残基是Lys691、Glu559、Asp767和His866[2]。Pravastatin sodium通过范德华力占据HMG-CoAR与HMG-CoA结合的结合口袋，从而降低胆固醇的合成[3]。
在体外，Pravastatin sodium（1μg/mL）处理不同葡萄糖浓度孵育的细胞滋养层（CTB）细胞，减轻了高血糖诱导的CTB 迁移功能障碍[4]。Pravastatin sodium（0-2000μM）处理内皮集落形成细胞（ECFC），显著增强了细胞的增殖、迁移和管形成能力，增加了蛋白激酶 B（AKT）和内皮一氧化氮合酶（eNOS）的磷酸化和血红素加氧酶-1（HO-1）、血管内皮生长因子 A （VEGF-A）和胎盘生长因子 （PlGF）的表达水平，但降低了可溶性 fms 样酪氨酸激酶-1（sFlt-1）和内皮糖蛋白（Eng）的表达水平[5]。
在体内，Pravastatin sodium（20mg/kg/day）通过口服治疗糖尿病大鼠8周，Pravastatin sodium虽然增加了糖尿病大鼠的体重，但是显著降低了糖原磷酸化酶、乳酸脱氢酶和葡萄糖-6-磷酸酶水平改善了糖尿病引起的肝酶不良反应，并降低空腹血糖水平，增加肝糖原含量[6]。Pravastatin sodium（20mg/kg/day）通过口服治疗通过异丙肾上腺素诱导的心脏纤维化小鼠14天，降低了CK-MB、血清甘油三酯、心脏组织胶原蛋白 I 和 III 水平、心脏炎症细胞和心脏纤维化水平[7]。
| Cell experiment [1]: | |
Cell lines | ECFC cells |
Preparation Method | ECFC cells were seeded into 6-well plates with 5 × 10 4 cells per well and cultured for 24h. The cell monolayers were scratched with a sterile P1000 pipette tip to create a wound. They were treated with different concentrations (0, 2, 20, 200, and 2000μM) of Pravastatin sodium. Phase contrast microscopic images were immediately obtained after scratching and then again after 18h. |
Reaction Conditions | 0, 2, 20, 200, and 2000μM; 18h |
Applications | Pravastatin sodium significantly improve the migration of ECFC cells. |
| Animal experiment [2]: | |
Animal models | Wistar albino rats |
Preparation Method | Female Wistar albino rats were used and diabetes was induced by intraperitoneal injection of streptozotocin. Thereafter, 10 and 20mg/kg/day doses of Pravastatin sodium were administered by oral gavage to the diabetic rats for 8 weeks. At the end of the experiment, the levels of fasting blood glucose, liver glycogen, and liver enzymes related to carbohydrate metabolism were measured. |
Dosage form | 10 and 20mg/kg/day for 8 weeks; p.o. |
Applications | Pravastatin sodium significantly reduced the liver glycogen synthase and pyruvate kinase levels, but increased the glycogen phosphorylase level in diabetic rats. |
References: | |
| Cas No. | 81131-70-6 | SDF | |
| 别名 | 普伐他汀钠; CS-514 sodium | ||
| 化学名 | sodium;(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoate | ||
| Canonical SMILES | CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)[O-])O)O)O.[Na+] | ||
| 分子式 | C23H35O7.Na | 分子量 | 446.51 |
| 溶解度 | ≥ 13.15 mg/mL in DMSO, ≥ 100.4 mg/mL in EtOH with ultrasonic, ≥ 98.8 mg/mL in Water | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2396 mL | 11.198 mL | 22.3959 mL |
| 5 mM | 0.4479 mL | 2.2396 mL | 4.4792 mL |
| 10 mM | 0.224 mL | 1.1198 mL | 2.2396 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet